

## **Aytu BioPharma to Report Fourth Quarter and Fiscal 2023 Financial Results on September 27, 2023**

**ENGLEWOOD, CO / September 21, 2023** / Aytu BioPharma, Inc. (the Company or “Aytu”) (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its fourth quarter and fiscal year ended June 30, 2023, after the market close on Wednesday, September 27, 2023. The Company has scheduled a conference call that same day, Wednesday, September 27, 2023, at 4:30 pm ET, to review the results.

### **Conference Call Information**

**Date and Time:** Wednesday, September 27, 2023, at 4:30 pm ET

**Call-in Information:** Interested parties can access the conference call by dialing (888) 506-0062 or (973) 528-0011 using the participant access code 381283.

**Webcast Information:** The webcast will be accessible live and archived at the following link, <https://www.webcaster4.com/Webcast/Page/2142/48975> and on Aytu BioPharma’s website, within the Investors section under Events & Presentations, at [aytubio.com](http://aytubio.com), for 90 days.

**Replay:** A teleconference replay of the call will be available until October 11, 2023 at (877) 481-4010 or (919) 882-2331, replay access code 48975.

### **About Aytu BioPharma, Inc.**

Aytu BioPharma is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s prescription products include Adzenys XR-ODT® (amphetamine) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) and Cotelpla XR-ODT® (methylphenidate) extended-release orally disintegrating tablets (see Full Prescribing Information, including Boxed WARNING) for the treatment of attention deficit hyperactivity disorder (ADHD), Karbinal® ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions, and Poly-Vi-Flor® and Tri-Vi-Flor®, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Aytu’s consumer health segment markets a range of over-the-counter medicines and consumer health products addressing a range of common conditions including diabetes, allergy, hair regrowth, and gastrointestinal conditions. To learn more, please visit [aytubio.com](http://aytubio.com).

### **Contacts for Investors:**

Mark Oki, Chief Financial Officer  
Aytu BioPharma, Inc.

moki@aytubio.com

Robert Blum or Roger Weiss

Lytham Partners

AYTU@lythampartners.com

**SOURCE:** Aytu BioPharma, Inc.

View source version on accesswire.com:

<https://www.accesswire.com/785296/aytu-biopharma-to-report-fourth-quarter-and-fiscal-2023-financial-results-on-september-27-2023>